These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 31238905)

  • 21. A phase II trial to evaluate the efficacy of panitumumab combined with fluorouracil-based chemotherapy for metastatic colorectal cancer: the PF trial.
    Munemoto Y; Kanda M; Oba K; Kim HM; Takemoto H; Denda T; Nagata N; Takano N; Fukunaga M; Kataoka M; Tokunaga Y; Sakamoto J; Mishima H
    Cancer Chemother Pharmacol; 2018 May; 81(5):829-838. PubMed ID: 29508026
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
    Tol J; Punt CJ
    Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status.
    Mitchell EP; Piperdi B; Lacouture ME; Shearer H; Iannotti N; Pillai MV; Xu F; Yassine M
    Clin Colorectal Cancer; 2011 Dec; 10(4):333-9. PubMed ID: 22000810
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase IB/II Study of Second-Line Therapy with Panitumumab, Irinotecan, and Everolimus (PIE) in
    Townsend A; Tebbutt N; Karapetis C; Cooper P; Singhal N; Yeend S; Pirc L; Joshi R; Hardingham J; Price T
    Clin Cancer Res; 2018 Aug; 24(16):3838-3844. PubMed ID: 29739790
    [No Abstract]   [Full Text] [Related]  

  • 25. A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the US.
    Graham CN; Christodoulopoulou A; Knox HN; Sabatelli L; Hechmati G; Garawin T; Strickler JH
    J Med Econ; 2018 Nov; 21(11):1075-1083. PubMed ID: 30091652
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status.
    Siena S; Rivera F; Taieb J; Peeters M; Prenen H; Koukakis R; Demonty G; Köhne CH
    Clin Colorectal Cancer; 2018 Mar; 17(1):50-57.e8. PubMed ID: 29096990
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rationale for and Design of the PARADIGM Study: Randomized Phase III Study of mFOLFOX6 Plus Bevacizumab or Panitumumab in Chemotherapy-naïve Patients With RAS (KRAS/NRAS) Wild-type, Metastatic Colorectal Cancer.
    Yoshino T; Uetake H; Tsuchihara K; Shitara K; Yamazaki K; Oki E; Sato T; Naitoh T; Komatsu Y; Kato T; Yamanaka K; Iwasaki K; Soeda J; Hihara M; Yamanaka T; Ochiai A; Muro K
    Clin Colorectal Cancer; 2017 Jun; 16(2):158-163. PubMed ID: 28237539
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multicenter phase II study of combination therapy with cetuximab and S-1 in patients with KRAS exon 2 wild-type unresectable colorectal cancer previously treated with irinotecan, oxaliplatin, and fluoropyrimidines (KSCC 0901 study).
    Takahashi T; Emi Y; Oki E; Kobayashi K; Tsuji A; Shimokawa M; Tanaka T; Akagi Y; Ogata Y; Baba H; Yoshida K; Natsugoe S; Maehara Y;
    Cancer Chemother Pharmacol; 2016 Sep; 78(3):585-93. PubMed ID: 27468920
    [TBL] [Abstract][Full Text] [Related]  

  • 29. STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer.
    Chibaudel B; Bonnetain F; Tournigand C; de Larauze MH; de Gramont A; Laurent-Puig P; Paget J; Hadengue A; Notelet D; Benetkiewicz M; André T; de Gramont A
    BMC Cancer; 2015 Jul; 15():496. PubMed ID: 26141683
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.
    Schwartzberg LS; Rivera F; Karthaus M; Fasola G; Canon JL; Hecht JR; Yu H; Oliner KS; Go WY
    J Clin Oncol; 2014 Jul; 32(21):2240-7. PubMed ID: 24687833
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I study of primary treatment with 5-FU, oxaliplatin, irinotecan, levofolinate, and panitumumab combination chemotherapy in patients with advanced/recurrent colorectal cancer involving the wild-type RAS gene: the JACCRO CC-14 study.
    Satake H; Tsuji A; Nakamura M; Ogawa M; Kotake T; Hatachi Y; Yasui H; Takagane A; Okita Y; Nakamura K; Onikubo T; Takeuchi M; Fujii M
    Int J Clin Oncol; 2018 Jun; 23(3):490-496. PubMed ID: 29464396
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II Study of Preoperative Treatment with External Radiotherapy Plus Panitumumab in Low-Risk, Locally Advanced Rectal Cancer (RaP Study/STAR-03).
    Pinto C; Di Bisceglie M; Di Fabio F; Bochicchio A; Latiano T; Cordio S; Rosati G; Aschele C; Marino A; Bergamo F; Bustreo S; Frassineti L; Ciardiello F; Damato A; Giaquinta S; Baldari D; Boni L
    Oncologist; 2018 Aug; 23(8):912-918. PubMed ID: 29523646
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multicenter Phase II Study of Panitumumab in Platinum Pretreated, Advanced Head and Neck Squamous Cell Cancer.
    Siano M; Molinari F; Martin V; Mach N; Früh M; Freguia S; Corradino I; Ghielmini M; Frattini M; Espeli V
    Oncologist; 2017 Jul; 22(7):782-e70. PubMed ID: 28592616
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Panitumumab: in metastatic colorectal cancer with wild-type KRAS.
    Weber J; McCormack PL
    BioDrugs; 2008; 22(6):403-11. PubMed ID: 18998757
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase Ib study of a PI3Kinase inhibitor BKM120 in combination with panitumumab in patients with KRAS wild-type advanced colorectal cancer.
    Goodwin R; Jonker D; Chen E; Kennecke H; Cabanero M; Tsao MS; Vickers M; Bohemier C; Lim H; Ritter H; Tu D; Seymour L
    Invest New Drugs; 2020 Aug; 38(4):1077-1084. PubMed ID: 31506897
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of Primary Tumor Location on Second- or Later-line Treatment Outcomes in Patients With RAS Wild-type Metastatic Colorectal Cancer and All Treatment Lines in Patients With RAS Mutations in Four Randomized Panitumumab Studies.
    Boeckx N; Koukakis R; Op de Beeck K; Rolfo C; Van Camp G; Siena S; Tabernero J; Douillard JY; André T; Peeters M
    Clin Colorectal Cancer; 2018 Sep; 17(3):170-178.e3. PubMed ID: 29627309
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Spotlight on panitumumab in metastatic colorectal cancer.
    Keating GM
    BioDrugs; 2010 Aug; 24(4):275-8. PubMed ID: 20623992
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of panitumumab in older patients with metastatic colorectal cancer: a retrospective analysis using the database of the Hellenic Oncology Research Group (HORG).
    Asimakopoulou N; Souglakos J; Kentepozidis N; Karampeazis A; Kotsakis A; Ziras N; Makrantonakis P; Prinarakis E; Vamvakas L; Georgoulias V;
    J Geriatr Oncol; 2019 Jan; 10(1):143-148. PubMed ID: 30366852
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Economic Analysis of Panitumumab Compared With Cetuximab in Patients With Wild-type KRAS Metastatic Colorectal Cancer That Progressed After Standard Chemotherapy.
    Graham CN; Maglinte GA; Schwartzberg LS; Price TJ; Knox HN; Hechmati G; Hjelmgren J; Barber B; Fakih MG
    Clin Ther; 2016 Jun; 38(6):1376-1391. PubMed ID: 27085587
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Review article: panitumumab--a fully human anti-EGFR monoclonal antibody for treatment of metastatic colorectal cancer.
    Peeters M; Balfour J; Arnold D
    Aliment Pharmacol Ther; 2008 Aug; 28(3):269-81. PubMed ID: 19086328
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.